[Federal Register: January 13, 2003 (Volume 68, Number 8)]
[Notices]
[Page 1619]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr13ja03-62]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 01N-0566]
Renee Peugeot; Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (the act) permanently
debarring Renee Peugeot from providing services in any capacity to a
person that has an approved or pending drug product application. FDA
bases this order on a finding that Ms. Peugeot was convicted of a
felony under Federal law for conduct relating to the development or
approval, including the process for development or approval, of a drug
product. Ms. Peugeot failed to request a hearing and, therefore, has
waived her opportunity for a hearing concerning this action.
DATES: This order is effective January 13, 2003.
ADDRESSES: Submit applications for termination of debarment to the
Dockets Management Branch (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Nicole K. Mueller, Center for Drug
Evaluation and Research (HFD-7), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-594-2041.
SUPPLEMENTARY INFORMATION:
I. Background
On August 31, 2000, the U.S. District Court for the Northern
District of Alabama entered judgment against Ms. Peugeot for two counts
of making false statements to an agency of the United States, two
counts of mail fraud, and one count of conspiracy to commit offenses
against the United States, Federal felony offenses under 18 U.S.C. 2,
1001, 1341, and 371, respectively. These offenses were committed as
part of the development of a new drug for which Ms. Peugeot was
conducting efficacy trials.
As a result of this conviction, FDA served Ms. Peugeot by certified
mail on May 8, 2002, a notice proposing to permanently debar Ms.
Peugeot from providing services in any capacity to a person that has an
approved or pending drug product application. The proposal also offered
Ms. Peugeot an opportunity for a hearing on the proposal. The proposal
was based on a finding, under section 306(a)(2)(A) of the act (21
U.S.C. 335a(a)(2)(A)), that Ms. Peugeot was convicted of a felony under
Federal law for conduct relating to the development or approval,
including the process for development or approval, of a drug product.
Ms. Peugeot was provided 30 days to file objections and request a
hearing. Ms. Peugeot did not request a hearing. Her failure to request
a hearing constitutes a waiver of her opportunity for a hearing and a
waiver of any contentions concerning her debarment.
II. Findings and Order
Therefore, the Director, Center for Drug Evaluation and Research,
under section 306(a)(2)(A) of the act, and under authority delegated to
her (21 CFR 5.34), finds that Ms. Renee Peugeot has been convicted of a
felony under Federal law for conduct relating to the development or
approval, including the process for development or approval, of a drug
product.
As a result of the foregoing finding, Ms. Renee Peugeot is
permanently debarred from providing services in any capacity to a
person with an approved or pending drug product application under
section 505, 512, or 802 of the act (21 U.S.C. 355, 360b, or 382), or
under section 351 of the Public Health Service Act (42 U.S.C. 262),
(see sections 306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd) of the act (21
U.S.C. 321(dd))). Any person with an approved or pending drug product
application who knowingly uses the services of Ms. Peugeot, in any
capacity, during her period of debarment, will be subject to civil
money penalties (section 307(a)(6) of the act (21 U.S.C. 335b(a)(6))).
If Ms. Peugeot, during her period of debarment, provides services in
any capacity to a person with an approved or pending drug product
application, she will be subject to civil money penalties (section
307(a)(7) of the act). In addition, FDA will not accept or review any
abbreviated new drug applications submitted by or with the assistance
of Ms. Peugeot during her period of debarment.
Any application by Ms. Peugeot for termination of debarment under
section 306(d)(4) of the act should be identified with Docket No. 01N-
0566 and sent to the Dockets Management Branch (see ADDRESSES). All
such submissions are to be filed in four copies. The public
availability of information in these submissions is governed by 21 CFR
10.20(j). Publicly available submissions may be seen in the Dockets
Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
Dated: December 23, 2002.
Janet Woodcock,
Director, Center for Drug Evaluation and Research.
[FR Doc. 03-663 Filed 1-10-03; 8:45 am]
BILLING CODE 4160-01-S